Citrine Medicine Announces Strategic Partnership to bring Alkindi® to China for Use in Pediatric Congenital Adrenal Hyperplasia (CAH)
- Wednesday, January 27, 2021, 7:04
- Finance
- Add a comment
CAMBRIDGE, Mass. and SHANGHAI, Jan. 27, 2021 /PRNewswire/ — Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has entered into a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical company targeting patient needs in…
About the Author
adminasapcorp has written 41532 stories on this site.